Which of the following regarding epoprostenol is FALSE?

The drug is selective

(D) is the false statement and is important clinically. Epoprostenol is NOT selective.Because epoprostenol is not selective, other drugs, such as other vasodilators, antiplatelets, and anticoagulants, have interactions with epoprostenol. In essence, epoprostenol acts on regular blood vessels in addition to the pulmonary vessels. This causes systemic problems and that certainly interacts with drugs that act in the systemic vasculature. (A) is true. Recall that prostacyclin is one of the elements that will promote vasodilation, which is desired here. As an analog, it will act as endogenous prostacyclin. (B) is also true and this is important. Two products, Flolan and Veletri, are on the market. And they each have their own characeristics. For instance, an infusion pump (CADD pump) is used in both products. This is how the patient administers epoprostenol at home. Flolan is particular in that it requires a sterile diluent that is unique for Flolan. Veletri can get away with sterile water and 0.9% sodium chloride as the diluent. Veletri doesnt need ice packs (Flolan does), and it is stable at room temperature (hence no ice packs). Both need back-up cassettes (just in case). (C) is also true. Improves mortality means that there is a survival benefit from the drug. There are improvements in exercise capacity and quality of life. Naturally, there are adverse effects such as flushing headache, and nausea. This is expected because of the vasodilation of the arteries leading to the brain.